国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
13期
1913-1915
,共3页
食管癌%放疗%适形%预后
食管癌%放療%適形%預後
식관암%방료%괄형%예후
Esophageal cancer%Radiotherapy%Conformal%Prognosis
目的 探讨食管癌放疗优化方案的临床效果.方法 选取60例食管癌患者,将其随机分为后程常规分割三维适形放疗组(对照组)和后程加速超分割三维适形放疗组(加超组).放疗方法均在前2/3疗程普通模拟机定位常规放疗40 Gy,后1/3疗程加超组改为CT模拟定位加速超分割三维适形放疗(剂量为1.5 Gy/次,2次/d,共计24 ~ 30Gy,总剂量为64 ~ 70Gy,36 ~ 40次,全疗程为38 ~ 42d);对照组采用常规分割三维适形放疗(剂量为2.0 Gy/次,1次/d,总剂量为64~70Gy).结果 加超组近期疗效明显优于对照组,差异有统计学意义(P<0.05);治疗后两组患者不良反应、并发症和1年生存率比较,差异均无统计学意义(P>0.05).结论 常规放疗后进行后程加速超分割三维适形放疗治疗食管癌的近期疗效明显提高,且不良反应未有增加,值得临床推广应用.
目的 探討食管癌放療優化方案的臨床效果.方法 選取60例食管癌患者,將其隨機分為後程常規分割三維適形放療組(對照組)和後程加速超分割三維適形放療組(加超組).放療方法均在前2/3療程普通模擬機定位常規放療40 Gy,後1/3療程加超組改為CT模擬定位加速超分割三維適形放療(劑量為1.5 Gy/次,2次/d,共計24 ~ 30Gy,總劑量為64 ~ 70Gy,36 ~ 40次,全療程為38 ~ 42d);對照組採用常規分割三維適形放療(劑量為2.0 Gy/次,1次/d,總劑量為64~70Gy).結果 加超組近期療效明顯優于對照組,差異有統計學意義(P<0.05);治療後兩組患者不良反應、併髮癥和1年生存率比較,差異均無統計學意義(P>0.05).結論 常規放療後進行後程加速超分割三維適形放療治療食管癌的近期療效明顯提高,且不良反應未有增加,值得臨床推廣應用.
목적 탐토식관암방료우화방안적림상효과.방법 선취60례식관암환자,장기수궤분위후정상규분할삼유괄형방료조(대조조)화후정가속초분할삼유괄형방료조(가초조).방료방법균재전2/3료정보통모의궤정위상규방료40 Gy,후1/3료정가초조개위CT모의정위가속초분할삼유괄형방료(제량위1.5 Gy/차,2차/d,공계24 ~ 30Gy,총제량위64 ~ 70Gy,36 ~ 40차,전료정위38 ~ 42d);대조조채용상규분할삼유괄형방료(제량위2.0 Gy/차,1차/d,총제량위64~70Gy).결과 가초조근기료효명현우우대조조,차이유통계학의의(P<0.05);치료후량조환자불량반응、병발증화1년생존솔비교,차이균무통계학의의(P>0.05).결론 상규방료후진행후정가속초분할삼유괄형방료치료식관암적근기료효명현제고,차불량반응미유증가,치득림상추엄응용.
Objective To explore the clinical efficacy of optimized radiotherapy for esophageal cancer.Methods 60 patients with esophageal cancer were randomly divided into two groups.The study group received conventional fractionated radiotherapy during the first two-thirds of the course with 40 Gy,then followed by hypeffraction 3D-CRT with 24-30 Gy for 12 to 18 days,with 1.5 Gy per fraction,and a total dose of 64-70 Gy in 36 -40 fractions for 38-42 days.The control group received the same therapy during the two-thirds of the course,but followed by conventional fractionated 3D-CRT with 2.0 Gy per fraction and a total dose of 64-70 Gy.Results The study group was superior to the control group in the short-term efficacy,with a statistical difference (P<0.05).There were no significant differences between the two groups in adverse reactions,complications,and one-year survival rate (P>0.05).Conclusions Hyperfraction 3D-CRT following conventional radiotherapy can improve the short-term efficacy of treatment for esophageal cancer and has no increase in adverse reactions.It is worth popularizing clinically.